Liquidia Corp (LQDA) is trading up at $39.69 (+2.14%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Current price targets from 3 firms average $47, median $53, ranging from $30 to $58 — the average is 18% above the current $39.7. Each is tracked to its date and scored the same way a member's call is.
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $8.07M | $739.6K | $12.9M | $15.9M | $17.5M | $14.0M | $158.3M |
| Growth (year over year) | — | −90.8% | +1637.8% | +24.0% | +9.7% | −20.0% | +1031.2% |
| Gross profit | — | $501.9K | $9.83M | $13.1M | $14.6M | $8.12M | — |
| Gross margin | — | 67.9% | 76.5% | 82.1% | 83.5% | 58.0% | — |
| Operating income | −$46.8M | −$59.1M | −$33.8M | −$38.8M | −$73.4M | −$121.3M | −$51.4M |
| Operating margin | −580.1% | −7989.0% | −263.0% | −243.3% | −419.6% | −866.6% | −32.5% |
| Net income | −$47.6M | −$59.8M | −$34.6M | −$41.0M | −$78.5M | −$128.3M | −$68.9M |
| Net margin | −589.5% | −8080.1% | −269.0% | −257.4% | −448.9% | −916.6% | −43.5% |
| EPS (diluted) | −$2.57 | −$1.76 | −$0.70 | −$0.67 | −$1.21 | −$1.63 | −$0.80 |
| Balance sheet | |||||||
| Cash and equivalents | $55.8M | $65.3M | $57.5M | $93.3M | $83.7M | $176.5M | $190.7M |
| Total assets | $68.8M | $99.5M | $93.7M | $129.2M | $118.3M | $230.3M | $327.9M |
| Total liabilities | $33.9M | $28.4M | $28.5M | $38.8M | $71.0M | $150.9M | $283.2M |
| Long-term debt | $10.3M | $10.3M | $10.4M | $19.9M | — | — | — |
| Shareholders' equity | $34.9M | $71.1M | $65.3M | $90.4M | $47.3M | $79.4M | $44.7M |
| Cash flow | |||||||
| Operating cash flow | −$48.3M | −$54.1M | −$34.0M | −$28.6M | −$41.6M | −$93.4M | −$35.7M |
| Capital expenditure | $1.85M | $752.1K | $107.0K | $592.0K | $1.29M | $4.95M | $4.34M |
| Free cash flow | −$50.1M | −$54.9M | −$34.1M | −$29.2M | −$42.9M | −$98.4M | −$40.0M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $4.45M | $2.92M | $3.12M | $8.84M | $54.3M | — | $132.9M | $171.7M |
| Growth (year over year) | +20.9% | −35.6% | +5.0% | +141.5% | +1121.7% | — | +4158.5% | +1842.7% |
| Gross profit | $2.88M | $1.56M | $1.60M | — | — | — | — | — |
| Gross margin | 64.8% | 53.6% | 51.4% | — | — | — | — | — |
| Operating income | −$29.2M | −$36.1M | −$35.4M | −$37.5M | $1.77M | — | $61.5M | $85.5M |
| Operating margin | −656.2% | −1237.8% | −1135.4% | −424.4% | 3.3% | — | 46.3% | 49.8% |
| Net income | −$31.0M | −$38.5M | −$38.4M | −$41.6M | −$3.53M | — | $52.9M | $74.7M |
| Net margin | −697.6% | −1320.2% | −1229.7% | −470.5% | −6.5% | — | 39.8% | 43.5% |
| EPS (diluted) | −$0.40 | −$0.45 | −$0.45 | −$0.49 | −$0.04 | — | $0.52 | $0.74 |
| Balance sheet | ||||||||
| Cash and equivalents | $204.4M | $176.5M | $169.8M | $173.4M | $157.5M | $190.7M | $222.8M | $284.2M |
| Total assets | $252.9M | $230.3M | $227.4M | $257.4M | $276.0M | $327.9M | $401.5M | $521.9M |
| Total liabilities | $142.4M | $150.9M | $177.7M | $242.2M | $253.9M | $283.2M | $293.0M | $326.8M |
| Shareholders' equity | $112.8M | $79.4M | $49.7M | $15.2M | $22.1M | $44.7M | $108.6M | $195.1M |
| Cash flow | ||||||||
| Operating cash flow | −$25.1M | −$20.8M | −$30.7M | −$39.5M | −$9.77M | — | $53.0M | $80.2M |
| Capital expenditure | $1.75M | $1.29M | $330.0K | $1.06M | $911.0K | — | $2.83M | $11.2M |
| Free cash flow | −$26.8M | −$22.1M | −$31.0M | −$40.5M | −$10.7M | — | $50.2M | $69.0M |
From Liquidia Corp's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Premarket movers: Alibaba gains on new AI glasses; Liquidia rallies as legal eases
Premarket movers: Alibaba gains on new AI glasses; Liquidia rallies as legal eases
Liquidia chief accounting officer Dana Boyle sells $167,804 in shares
Liquidia chief accounting officer Dana Boyle sells $167,804 in shares
Liquidia CBO Jason Adair sells $207,932 in shares after vesting
Liquidia CBO Jason Adair sells $207,932 in shares after vesting
Liquidia (NASDAQ:LQDA) CMO Rajeev Saggar disposes of $262,528 in stock
Liquidia (NASDAQ:LQDA) CMO Rajeev Saggar disposes of $262,528 in stock
Liquidia CCO Scott Moomaw sells $252,418 in company stock
Liquidia CCO Scott Moomaw sells $252,418 in company stock
Liquidia Corp general counsel Schundler sells $389,948 of stock
Liquidia Corp general counsel Schundler sells $389,948 of stock
Liquidia chief human resources officer Sarah Krepp sells $149,377 in company stock
Liquidia chief human resources officer Sarah Krepp sells $149,377 in company stock
Liquidia Corp chief development officer sells $31,356 in stock
Liquidia Corp chief development officer sells $31,356 in stock
Liquidia CFO Michael Kaseta sells $539,354 in LQDA shares
Liquidia CFO Michael Kaseta sells $539,354 in LQDA shares
Liquidia stock surges 40% on $380.7M litigation settlement with UTHR
Liquidia stock surges 40% on $380.7M litigation settlement with UTHR
Liquidia settles all litigation with United Therapeutics
Liquidia settles all litigation with United Therapeutics
Raymond James reiterates Liquidia stock rating amid legal filings
Raymond James reiterates Liquidia stock rating amid legal filings
Liquidia stock price target cut to $58 by H.C. Wainwright on patent uncertainty
Liquidia stock price target cut to $58 by H.C. Wainwright on patent uncertainty